Podchaser Logo
Home
Samantha Semenkow - Biotech Valuation in the Public Markets

Samantha Semenkow - Biotech Valuation in the Public Markets

Released Monday, 9th August 2021
Good episode? Give it some love!
Samantha Semenkow - Biotech Valuation in the Public Markets

Samantha Semenkow - Biotech Valuation in the Public Markets

Samantha Semenkow - Biotech Valuation in the Public Markets

Samantha Semenkow - Biotech Valuation in the Public Markets

Monday, 9th August 2021
Good episode? Give it some love!
Rate Episode

Sam Semenkow, Ph.D. is a Director of Portfolio Intelligence at Bridge Bio, a unique biotechnology company that develops drugs in several modalities for a number of diverse disease areas. Prior to joining Bridge Bio, Sam was an Associate in the equity research group at Citi, a multinational bank. As an equity research associate, Sam covered a number of public biotech companies- applying valuations and building financial models for commercial and clinical stage drug candidates. Sam holds a Ph.D from the Johns Hopkins School of Medicine. In this episode, Sam discusses the hiring process for equity research groups for individuals with advanced degrees. She also describes the type of work one would do while working in equity research. We finish the episode with a description of Bridge Bio, and a discussion on assessing risk in biotech.


Hosted by Roshan Chikarmane, Jenna Glatzer, and Joe Varriale. 



Show More
Rate

Join Podchaser to...

  • Rate podcasts and episodes
  • Follow podcasts and creators
  • Create podcast and episode lists
  • & much more

Episode Tags

Do you host or manage this podcast?
Claim and edit this page to your liking.
,

Unlock more with Podchaser Pro

  • Audience Insights
  • Contact Information
  • Demographics
  • Charts
  • Sponsor History
  • and More!
Pro Features